References
- Freedman A. M., Fink M., Sharoff R., Zaks A. Cyclazocine and methadone in narcotic addiction. J. Am. Med. Assoc. 1967; 202: 191–194
- Jaffee J. H., Brill L. Cyclazocine, a long acting narcotic antagonist: Its voluntary acceptance as a treatment modality by narcotics abusers. Int. J. Addict. 1966; 1: 99–123
- Jasinskl D. R., Martin W. R., Haertzen C. A. The human pharmacology and abuse potential of N-Allynoroxymorphone (naloxone). J. Pharmacol. Exp. Ther. 1967; 157: 420–426
- Martin W. R., Gorodetzky C. W., McClane T. K. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther. 1966; 7: 455–465
- Martin W. R., Jasinski D. R., Mansky P. A. Characteristics of the blocking effects of EN-1639A. Proceedings of the Committee on Problems of Drug Dependence 1971, National Research Council Report 179–191
- Martin W. R., Jasinski D. R., Mansky P. A. Naltrexone, an antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatry 1973; 28: 784–791
- Meyer R. E., Mirin S. M., Altman J. L., McNamee H. B. A behavioral paradigm for the evaluation of narcotic antagonists. Arch. Gen. Psychiatry 1976; 33: 371–377
- O'Brien C. P., Greenstein R. A., Mintz J., Woody G. E. Clinical experience with naltrexone. Am. J. Drug Alcohol Abuse 1975; 2: 365–377
- Resnick R. B., Volavka J., Freedman A. M., Thomas M. Studies of EN-1639A naltrexone: A new narcotic antagonist. Am. J. Psychiatry 1974; 131: 646–650